Literature DB >> 3209531

Inhibitory antimicrobial concentrations against Campylobacter pylori in gastric mucosa.

C A McNulty1, J C Dent, G A Ford, S P Wilkinson.   

Abstract

Gastric mucosal concentrations of erythromycin, amoxycillin, ampicillin and ciprofloxacin were determined in patients at upper gastrointestinal endoscopy 38-480 min after a 500 mg dose of erythromycin ethyl succinate, erythromycin stearate, amoxycillin, pivampicillin or ciprofloxacin. All the agents attained concentrations greater than the MIC 90 for Campylobacter pylori. The macrolides attained the lowest concentrations. There was no significant difference between concentrations attained with erythromycin ethyl succinate and stearate. High concentrations were attained by amoxycillin (range 14.6-322 mg/kg) and pivampicillin (range 47.5-209 mg/kg). Ciprofloxacin attained very high concentrations (range 35-1762 mg/kg); inhibitory concentrations 35 mg/kg) were still present at 6 h after the dose. Ciprofloxacin and erythromycin are ineffective in vivo despite these high gastric mucosal concentrations. Penetration into the gastric mucus and crypts where C. pylori is found will be determined by physicochemical properties of the antimicrobials, such as pKa, stability, activity over a wide range of pH, and lipid solubility.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3209531     DOI: 10.1093/jac/22.5.729

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  31 in total

1.  Challenging the dogma: a randomized trial of standard vs. half-dose concomitant nonbismuth quadruple therapy for Helicobacter pylori infection.

Authors:  Ala I Sharara; Fayez S Sarkis; Mustapha M El-Halabi; Ahmad Malli; Nabil M Mansour; Cecilio Azar; Mohamad A Eloubeidi; Fadi H Mourad; Kassem Barada; Ismail Sukkarieh
Journal:  United European Gastroenterol J       Date:  2014-06       Impact factor: 4.623

2.  Local gastric and serum concentrations of rebamipide following oral ingestion in healthy volunteers.

Authors:  Taiji Akamatsu; Naoshi Nakamura; Naoyuki Furuya; Toshiki Shimizu; Akira Gotou; Kendo Kiyosawa; Tsutomu Katsuyama; Takahiko Osumi; Yukihiro Hirao; Gohatiro Miyamoto
Journal:  Dig Dis Sci       Date:  2002-06       Impact factor: 3.199

3.  Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori.

Authors:  T Iwahi; H Satoh; M Nakao; T Iwasaki; T Yamazaki; K Kubo; T Tamura; A Imada
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

4.  In vitro activities of new oral beta-lactams and macrolides against Campylobacter pylori.

Authors:  J A García-Rodríguez; J E García Sánchez; M I García García; E García Sánchez; J L Muñoz Bellido
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

5.  In vitro selection of resistant Helicobacter pylori.

Authors:  C E Haas; D E Nix; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

6.  Effect of an acidic environment on the susceptibility of Helicobacter pylori to trospectomycin and other antimicrobial agents.

Authors:  Y J Debets-Ossenkopp; F Namavar; D M MacLaren
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-04       Impact factor: 3.267

7.  In vitro activities of new quinolones against Helicobacter pylori.

Authors:  M Carbone; M T Fera; V Cecchetti; O Tabarrini; E Losi; V Cusumano; G Teti
Journal:  Antimicrob Agents Chemother       Date:  1997-12       Impact factor: 5.191

8.  Azithromycin levels in plasma and gastric tissue, juice and mucus.

Authors:  J D Harrison; J A Jones; D L Morris
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

9.  Eradication of Helicobacter mustelae from the ferret stomach: an animal model of Helicobacter (Campylobacter) pylori chemotherapy.

Authors:  G Otto; J G Fox; P Y Wu; N S Taylor
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

10.  Nitazoxanide, a potential drug for eradication of Helicobacter pylori with no cross-resistance to metronidazole.

Authors:  F Mégraud; A Occhialini; J F Rossignol
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.